New York Life Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

New York Life Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-56,959	Closed	-$463K	–	1429
2023 Q4	$463K	Sell	56,959 -1,314	-2%	-$6.88K	﹤0.01%	883
2023 Q3	$265K	Sell	58,273 -9,179	-14%	-$59.9K	﹤0.01%	1224
2023 Q2	$475K	Sell	67,452 -3,802	-5%	-$27.2K	﹤0.01%	761
2023 Q1	$435K	Buy	+71,254	New	+$492K	﹤0.01%	1144

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

New York Life Investment Management's IOVA Position: Q1 2024 in Review

New York Life Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2024, closing a stake of 56,959 shares — an estimated $463K sold.

New York Life Investment Management first reported a position in IOVA in Q1 2023 and held it in 4 quarters. The position peaked at $475K in Q2 2023. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

New York Life Investment Management reported no remaining Iovance Biotherapeutics position as of Q1 2024 after selling out during the quarter.
New York Life Investment Management sold 56,959 Iovance Biotherapeutics shares in Q1 2024, an estimated $463K.
New York Life Investment Management first reported a position in Iovance Biotherapeutics in Q1 2023 and held it in 4 quarters.
New York Life Investment Management's Iovance Biotherapeutics position peaked at $475K in Q2 2023.
273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.